摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-Benzyl-1,4-dioxaspiro[4.5]dec-7-ene | 81842-02-6

中文名称
——
中文别名
——
英文名称
8-Benzyl-1,4-dioxaspiro[4.5]dec-7-ene
英文别名
——
8-Benzyl-1,4-dioxaspiro[4.5]dec-7-ene化学式
CAS
81842-02-6
化学式
C15H18O2
mdl
——
分子量
230.3
InChiKey
WPFQOARMQLDYCY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • CYCLOHEXYL(ALKYL)PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    申请人:Bovy Philippe R.
    公开号:US20080261949A1
    公开(公告)日:2008-10-23
    The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O) z (C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —SO 2 NH(C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl group or an —NHSO 2 phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C 1 -C 4 )alkyl group or with a (C 1 -C 4 )alkoxy group; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, a phenyl-(C 1 -C 4 )alkyl group or a —COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C 1 -C 4 )alkoxy group; R 2 is a hydrogen atom or an —SO 2 (C 1 -C 4 )alkyl group, an —SO 2 phenyl-(C 1 -C 4 )alkyl group or an —SO 2 phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C 1 -C 4 )alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R 3 represents a hydrogen or halogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 4 )alkoxy group, a —COO(C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl groups, —NO 2 , —CN, —CONR 4 R 5 , —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R 4 and R 5 represent, independently, a hydrogen atom, a phenyl, a (C 1 -C 4 )alkyl group or a phenyl-(C 1 -C 4 )alkyl group or R 4 and R 5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.
    本发明涉及公式(I)的化合物: 其中A是公式(a)或(b)的基团: 其中R表示氢或卤素原子,-S(O)z(C1-C4)烷基,-NHSO2(C1-C4)烷基,-SO2NH(C1-C4)烷基,-NHSO2苯基-(C1-C4)烷基或-NHSO2苯基,所述苯基可能被卤素原子,(C1-C4)烷基或(C1-C4)氧烷基取代; R1表示氢原子或(C1-C4)烷基,-CO(C1-C4)烷基,苯基-(C1-C4)烷基或-CO苯基,所述苯基也可能被卤素原子或(C1-C4)氧烷基取代; R2是氢原子或-SO2(C1-C4)烷基,-SO2苯基-(C1-C4)烷基或-SO2苯基; X完成由5到8个原子组成的环,该环饱和或不饱和,可能被一个或两个(C1-C4)烷基取代,并带有一个或两个羰基基团; n,m和z独立地为0、1或2; R3表示氢或卤素原子,(C1-C6)烷基,(C1-C4)氧烷基,-COO(C1-C4)烷基,-CO(C1-C4)烷基,-NHSO2(C1-C4)烷基,-NHSO2苯基-(C1-C4)烷基,-NO2,-CN,-CONR4R5,-COOH或4,5-二氢-1,3-噁唑-2-基或4,4-二甲基-4,5-二氢-1,3-噁唑-2-基; R4和R5独立地表示氢原子,苯基,(C1-C4)烷基或苯基-(C1-C4)烷基,或R4和R5与它们附着的氮原子一起可以形成总共5到7个原子的环;以及其盐或溶剂,含有它们的制药组合物,制备过程和其中间体的本发明。
  • Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same
    申请人:BOVY R. Philippe
    公开号:US20070015745A1
    公开(公告)日:2007-01-18
    The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O) z (C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —SO 2 NH(C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl group or an —NHSO 2 phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C 1 -C 4 )alkyl group or with a (C 1 -C 4 )alkoxy group; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, a phenyl-(C 1 -C 4 )alkyl group or a —CO—phenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C 1 -C 4 )alkoxy group; R 2 is a hydrogen atom or an —SO 2 (C 1 -C 4 )alkyl group, an —SO 2 phenyl-(C 1 -C 4 )alkyl group or an —SO 2 phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C 1 -C 4 )alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R 3 represents a hydrogen or halogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 4 )alkoxy group, a —COO(C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl groups, —NO 2 , —CN, —CONR 4 R 5 , —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4 and R 5 represent, independently, a hydrogen atom, a phenyl, a (C 1 -C 4 )alkyl group or a phenyl-(C 1 -C 4 )alkyl group or R 4 and R 5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.
    本发明涉及式(I)的化合物: 其中,A是式(a)或(b)的基团: 其中,R代表氢或卤素原子,-S(O)z(C1-C4)烷基,-NHSO2(C1-C4)烷基,-SO2NH(C1-C4)烷基,-NHSO2苯基-(C1-C4)烷基或-NHSO2苯基,所述苯可能被卤素原子,(C1-C4)烷基或(C1-C4)氧代基取代;R1代表氢原子或(C1-C4)烷基,-CO(C1-C4)烷基,苯基-(C1-C4)烷基或-CO-苯基,所述苯也可能被卤素原子或(C1-C4)氧代基取代;R2是氢原子或-SO2(C1-C4)烷基,-SO2苯基-(C1-C4)烷基或-SO2苯基;X完成一个由5到8个原子组成的环,该环饱和或不饱和,可能被一个或两个(C1-C4)烷基取代,并带有一个或两个羰基基团;n,m和z独立地为0,1或2;R3代表氢或卤素原子,(C1-C6)烷基,(C1-C4)氧代基,-COO(C1-C4)烷基,-CO(C1-C4)烷基,-NHSO2(C1-C4)烷基,-NHSO2苯基-(C1-C4)烷基,-NO2,-CN,-CONR4R5,-COOH或4,5-二氢-1,3-噁唑-2-基或4,4-二甲基-4,5-二氢-1,3-噁唑-2-基;R4和R5独立地代表氢原子,苯基,(C1-C4)烷基或苯基-(C1-C4)烷基,或R4和R5与它们所连接的氮原子可以总共形成一个由5到7个原子组成的环;以及它们的盐或溶剂合物,含有它们的制药组合物,制备它们的过程以及在该过程中的中间体。
  • US7388031B2
    申请人:——
    公开号:US7388031B2
    公开(公告)日:2008-06-17
  • US7419974B2
    申请人:——
    公开号:US7419974B2
    公开(公告)日:2008-09-02
  • US7718646B2
    申请人:——
    公开号:US7718646B2
    公开(公告)日:2010-05-18
查看更多